Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease. It is also known as N-butyldeoxynojirimycin, and is a derivative of the anti-diabetic 1-deoxynojirimycin. It was developed by Oxford GlycoSciences and is marketed by Actelion.